Amir Arsalan Ghahari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amir Arsalan Ghahari has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Mehrdad Nourizadeh
Neurosciences Research Center Tabriz University of Medical Sciences Tabriz Iran
4 shared publications - Shaghayegh Davari
Neurosciences Research Center Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Abdusaid Khasanov
Department of Family Medicine No. 2 and Clinical Pharmacology Tashkent State Medical University Tashkent Uzbekistan
1 shared publication - Afaq Mahdi Ali
College of Pharmacy, Department of Pharmaceutical Sciences, AL-Turath University, Baghdad, Iraq
1 shared publication - Ainur Sadykova
Department of Infectious and Tropical Diseases, Kazakh National Medical University Named After S.D. Asfendiyarov, Almaty 050044, Kazakhstan
1 shared publication - Arash Zarei
Department of Veterinary Medicine, Sho.C. Islamic Azad University Shoushtar Iran
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by Wiley in Clinical and Translational Discovery
- Vol. 6 (5) , e70211
CRISPR‐based therapeutic and modelling approaches in Huntington's disease: Progress, challenges and future directions
Background: Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG‐repeat expansion in exon 1 of the huntingtin gene ( HTT ). Mutant huntingtin accumulation and somatic repeat expansion contribute to neuronal dysfunction, making HD a compelling target for CRISPR‐based intervention. Objective: To evaluate CRISPR technologies for HTT modulation, validation of somatic CAG‐expansion modifiers, and HD modeling, with emphasis on efficacy, selectivity, delivery, and safety. Methods: This narrative review synthesizes preclinical evidence on DNA‐targeting nucleases, CRISPR interference, RNA‐targeting Cas13 systems, repeat stabilization, functional screens, and cellular and animal models. Approaches are compared by mechanism, durability, allele selectivity, central nervous system delivery, and translational limitations. Results: Cas9‐based strategies can disrupt HTT or excise exon 1, while SNP‐linked PAMs and guide mismatches may enable allele‐selective editing in genetically eligible patients. dCas9‐KRAB represses HTT transcription without DNA cleavage, whereas RfxCas13d/CasRx reduces HTT RNA without permanent genome modification; for both, selectivity and durability depend on guide design and delivery. CRISPR screens have identified expansion‐promoting DNA repair factors, including MSH3, MLH3, and PMS1, whereas protective factors such as FAN1 should be preserved. CAG‐to‐CAA base editing offers a complementary repeat‐stabilizing strategy. CRISPR‐corrected isogenic induced pluripotent stem cell‐derived neurons, organoids, and CRISPR‐generated large‐animal models strengthen mechanistic studies; conventional Q140 and zQ175 knock‐in mice remain useful for testing interventions but were not generated using CRISPR. Evidence remains preclinical. Major barriers include brain‐wide delivery, incomplete neuronal coverage, loss of wild‐type HTT function, heterogeneous on‐target repair, off‐target DNA or RNA activity, immune responses, durability, patient stratification, and long‐term safety. Conclusions: CRISPR is a versatile platform for HD research and development, but no approach yet combines adequate central nervous system distribution, mutant‐allele selectivity, durable neurological benefit, and established long‐term safety. Clinical translation requires comparative studies, allele‐resolved and genome‐wide safety assessment, validated delivery systems and biomarkers, and long‐term evaluation in disease‐relevant models.
- 18 September 2026
- Published by Wiley in Clinical and Translational Discovery
- Vol. 6 (5) , e70211
Open AccessCRISPR‐based therapeutic and modelling approaches in Huntington's disease: Progress, challenges and future directions
Background: Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG‐repeat expansion in exon 1 of the huntingtin gene ( HTT ). Mutant huntingtin accumulation and somatic repeat expansion contribute to neuronal dysfunction, making HD a compelling target for CRISPR‐based intervention. Objective: To evaluate CRISPR technologies for HTT modulation, validation of somatic CAG‐expansion modifiers, and HD modeling, with emphasis on efficacy, selectivity, delivery, and safety. Methods: This narrative review synthesizes preclinical evidence on DNA‐targeting nucleases, CRISPR interference, RNA‐targeting Cas13 systems, repeat stabilization, functional screens, and cellular and animal models. Approaches are compared by mechanism, durability, allele selectivity, central nervous system delivery, and translational limitations. Results: Cas9‐based strategies can disrupt HTT or excise exon 1, while SNP‐linked PAMs and guide mismatches may enable allele‐selective editing in genetically eligible patients. dCas9‐KRAB represses HTT transcription without DNA cleavage, whereas RfxCas13d/CasRx reduces HTT RNA without permanent genome modification; for both, selectivity and durability depend on guide design and delivery. CRISPR screens have identified expansion‐promoting DNA repair factors, including MSH3, MLH3, and PMS1, whereas protective factors such as FAN1 should be preserved. CAG‐to‐CAA base editing offers a complementary repeat‐stabilizing strategy. CRISPR‐corrected isogenic induced pluripotent stem cell‐derived neurons, organoids, and CRISPR‐generated large‐animal models strengthen mechanistic studies; conventional Q140 and zQ175 knock‐in mice remain useful for testing interventions but were not generated using CRISPR. Evidence remains preclinical. Major barriers include brain‐wide delivery, incomplete neuronal coverage, loss of wild‐type HTT function, heterogeneous on‐target repair, off‐target DNA or RNA activity, immune responses, durability, patient stratification, and long‐term safety. Conclusions: CRISPR is a versatile platform for HD research and development, but no approach yet combines adequate central nervous system distribution, mutant‐allele selectivity, durable neurological benefit, and established long‐term safety. Clinical translation requires comparative studies, allele‐resolved and genome‐wide safety assessment, validated delivery systems and biomarkers, and long‐term evaluation in disease‐relevant models.
- Open Access
- 10 August 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (5)
Artificial Intelligence in Veterinary Neurology: Comparative Insights From Human Medicine and Cross‐Species Technology Transfer
Background: Artificial intelligence (AI) is increasingly explored in veterinary neurology for pattern recognition, prediction and clinical decision support, with relevance to comparative and translational neuroscience. Objectives: This review examines AI applications in veterinary neurology, compares them with human neurology and evaluates cross‐species technology transfer within a One Health framework. Methods: A narrative review synthesized evidence across AI domains in veterinary neurology, including neuroimaging and radiomics, electrophysiology and seizure detection or forecasting, gait and pain assessment, morphometric biomarker discovery, prognostic modelling and laboratory diagnostic tools. Human studies were considered to identify translational opportunities, methodological challenges and the value of transfer learning and domain adaptation. Results: Available evidence suggests that AI holds promise for pattern recognition, prediction and decision support in veterinary neurology. Reported applications include canine brain tumour classification, spinal lesion grading, seizure monitoring and quantitative gait analysis, with encouraging performance. However, most applications remain proof‐of‐concept. The evidence base is dominated by retrospective single‐centre studies with small samples, heterogeneous protocols and limited prospective or external validation. Model calibration, uncertainty reporting and clinically relevant error trade‐offs are often insufficiently addressed. Transfer learning and domain adaptation may help overcome limited veterinary datasets, while naturally occurring neurological disease in dogs may also support refinement of human AI systems. Conclusions: AI in veterinary neurology is a promising but early field. Future progress will require multi‐centre collaboration, standardized data practices, explainable and ethically governed models and stronger One Health partnerships to support safe translation.
- 10 August 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (5)
Open AccessArtificial Intelligence in Veterinary Neurology: Comparative Insights From Human Medicine and Cross‐Species Technology Transfer
Background: Artificial intelligence (AI) is increasingly explored in veterinary neurology for pattern recognition, prediction and clinical decision support, with relevance to comparative and translational neuroscience. Objectives: This review examines AI applications in veterinary neurology, compares them with human neurology and evaluates cross‐species technology transfer within a One Health framework. Methods: A narrative review synthesized evidence across AI domains in veterinary neurology, including neuroimaging and radiomics, electrophysiology and seizure detection or forecasting, gait and pain assessment, morphometric biomarker discovery, prognostic modelling and laboratory diagnostic tools. Human studies were considered to identify translational opportunities, methodological challenges and the value of transfer learning and domain adaptation. Results: Available evidence suggests that AI holds promise for pattern recognition, prediction and decision support in veterinary neurology. Reported applications include canine brain tumour classification, spinal lesion grading, seizure monitoring and quantitative gait analysis, with encouraging performance. However, most applications remain proof‐of‐concept. The evidence base is dominated by retrospective single‐centre studies with small samples, heterogeneous protocols and limited prospective or external validation. Model calibration, uncertainty reporting and clinically relevant error trade‐offs are often insufficiently addressed. Transfer learning and domain adaptation may help overcome limited veterinary datasets, while naturally occurring neurological disease in dogs may also support refinement of human AI systems. Conclusions: AI in veterinary neurology is a promising but early field. Future progress will require multi‐centre collaboration, standardized data practices, explainable and ethically governed models and stronger One Health partnerships to support safe translation.
- Open Access
- 29 July 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (4)
Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes
Akkermansia muciniphila is increasingly linked to host metabolic, immune, and neurobehavioral phenotypes, yet taxon‐level associations are often inconsistent across studies and disease contexts. This review advances an effector‐centered framework to explain how A. muciniphila acts through host‐facing molecules, including outer membrane and secreted proteins such as Amuc_1100 (pilus‐associated signaling, PAS) and P9, extracellular vesicles (EVs) and outer membrane vesicles (OMVs), and shed cell‐envelope fragments and lipids. We synthesize evidence spanning barrier biology, immunometabolic regulation, infection and inflammatory injury, cancer immunology, and microbiota–gut–brain axis research. Across models, effectors modulate the mucus and epithelial barrier to limit translocation and dampen Toll‐like receptor (TLR) signaling, but mucus‐active enzymes or antigenic epitopes may also create liabilities in susceptible hosts. Defined effectors can reproduce key whole‐cell effects: in high‐fat diet (HFD)/carbon tetrachloride (CCl4) liver injury, vesicle preparations matched or exceeded pasteurized bacteria; Amuc_1100 maps to immune reprogramming and barrier signaling; and P9 links microbial cues to glucagon‐like peptide 1 (GLP‐1) release. Key gaps include physiological dose realism, equivalence across colony‐forming units (CFU) and protein or vesicle doses, strain and culture‐condition dependence of effector expression, and limited human data for brain‐relevant endpoints. Effector‐defined preparations and engineered delivery systems may improve standardization and safety, but translation will require rigorous characterization, dose‐response validation, and mechanism‐linked biomarkers.
- 29 July 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (4)
Open AccessDecoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes
Akkermansia muciniphila is increasingly linked to host metabolic, immune, and neurobehavioral phenotypes, yet taxon‐level associations are often inconsistent across studies and disease contexts. This review advances an effector‐centered framework to explain how A. muciniphila acts through host‐facing molecules, including outer membrane and secreted proteins such as Amuc_1100 (pilus‐associated signaling, PAS) and P9, extracellular vesicles (EVs) and outer membrane vesicles (OMVs), and shed cell‐envelope fragments and lipids. We synthesize evidence spanning barrier biology, immunometabolic regulation, infection and inflammatory injury, cancer immunology, and microbiota–gut–brain axis research. Across models, effectors modulate the mucus and epithelial barrier to limit translocation and dampen Toll‐like receptor (TLR) signaling, but mucus‐active enzymes or antigenic epitopes may also create liabilities in susceptible hosts. Defined effectors can reproduce key whole‐cell effects: in high‐fat diet (HFD)/carbon tetrachloride (CCl4) liver injury, vesicle preparations matched or exceeded pasteurized bacteria; Amuc_1100 maps to immune reprogramming and barrier signaling; and P9 links microbial cues to glucagon‐like peptide 1 (GLP‐1) release. Key gaps include physiological dose realism, equivalence across colony‐forming units (CFU) and protein or vesicle doses, strain and culture‐condition dependence of effector expression, and limited human data for brain‐relevant endpoints. Effector‐defined preparations and engineered delivery systems may improve standardization and safety, but translation will require rigorous characterization, dose‐response validation, and mechanism‐linked biomarkers.
- Open Access
- 15 April 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (7) , 3179-3190
Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases
Klotho, a pleiotropic protein initially identified for its role in kidney function, has garnered significant attention for its neuroprotective properties in various neurodegenerative diseases. It regulates key processes, such as oxidative stress, neuroinflammation, synaptic plasticity and myelination, all crucial for maintaining neuronal integrity and cognitive function. Preclinical studies demonstrate that klotho enhances amyloid‐β and tau clearance, stabilizes synaptic function, supports oligodendrocyte maturation and mitigates excitotoxicity. Clinical findings show that higher α‐klotho levels are associated with slower cognitive decline in Alzheimer's and Parkinson's diseases, improved outcomes in multiple sclerosis and better recovery after stroke. Notably, the protective effects of klotho appear most pronounced in individuals with high genetic or pathological risks, such as apolipoprotein E ε4 carriers in Alzheimer's disease. Despite these promising insights, the clinical application of klotho‐based therapies is hindered by variability in biomarker assays, challenges in crossing the blood–brain barrier, and the need for precision‐based interventions tailored to individual genetic profiles. Current strategies to enhance klotho activity include lifestyle changes, pharmacological agents, recombinant protein delivery and gene therapy. Although challenges remain, klotho stands as a potential therapeutic target for mitigating cognitive decline and promoting brain health across a range of neurodegenerative and cerebrovascular conditions.
- 15 April 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (7) , 3179-3190
Open AccessNeuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases
Klotho, a pleiotropic protein initially identified for its role in kidney function, has garnered significant attention for its neuroprotective properties in various neurodegenerative diseases. It regulates key processes, such as oxidative stress, neuroinflammation, synaptic plasticity and myelination, all crucial for maintaining neuronal integrity and cognitive function. Preclinical studies demonstrate that klotho enhances amyloid‐β and tau clearance, stabilizes synaptic function, supports oligodendrocyte maturation and mitigates excitotoxicity. Clinical findings show that higher α‐klotho levels are associated with slower cognitive decline in Alzheimer's and Parkinson's diseases, improved outcomes in multiple sclerosis and better recovery after stroke. Notably, the protective effects of klotho appear most pronounced in individuals with high genetic or pathological risks, such as apolipoprotein E ε4 carriers in Alzheimer's disease. Despite these promising insights, the clinical application of klotho‐based therapies is hindered by variability in biomarker assays, challenges in crossing the blood–brain barrier, and the need for precision‐based interventions tailored to individual genetic profiles. Current strategies to enhance klotho activity include lifestyle changes, pharmacological agents, recombinant protein delivery and gene therapy. Although challenges remain, klotho stands as a potential therapeutic target for mitigating cognitive decline and promoting brain health across a range of neurodegenerative and cerebrovascular conditions.
- Open Access
- 28 February 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (5) , 2449-2463
Psychobiotics and the microbiota–gut–brain axis: Emerging paradigms in mental health modulation
The global rise in mental health conditions has prompted interest in interventions that act beyond conventional psychopharmacology. Psychobiotics, broadly understood as live microorganisms or microbe‐derived products that interact with the microbiota–gut–brain axis, have been suggested to exert neuroactive effects through neural, immune, endocrine and metabolic routes. This narrative review synthesizes recent preclinical, mechanistic and early clinical observations. Experimental studies show that selected strains can modulate cytokine signalling, influence stress‐responsive systems such as the hypothalamic–pituitary–adrenal axis, and support synaptic plasticity via factors such as brain‐derived neurotrophic factor. A limited number of human trials using well‐characterized Lactobacillus and Bifidobacterium strains have reported improvements in affective and stress‐related outcomes, but these effects are generally small to moderate, more apparent in adjunctive than stand‐alone use, and dependent on strain, dose, population and intervention length (typically 4–12 weeks). Evidence on neurodevelopmental conditions (e.g., autism spectrum disorder, attention‐deficit/hyperactivity disorder) remains preliminary, based on small and heterogeneous samples. Across studies, key constraints include methodological heterogeneity, incomplete strain‐level reporting, and gaps in mechanistic resolution that make it difficult to link microbial shifts to psychiatric benefit. Emerging microbiome‐ and metabolomics‐informed approaches may help identify likely responders and improve translational precision, but they are not yet ready for routine clinical application. Overall, psychobiotics should currently be viewed as a promising adjunct within integrative mental health care, warranting larger, standardized trials with clearly defined strains, doses and mechanistic endpoints.
- 28 February 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (5) , 2449-2463
Open AccessPsychobiotics and the microbiota–gut–brain axis: Emerging paradigms in mental health modulation
The global rise in mental health conditions has prompted interest in interventions that act beyond conventional psychopharmacology. Psychobiotics, broadly understood as live microorganisms or microbe‐derived products that interact with the microbiota–gut–brain axis, have been suggested to exert neuroactive effects through neural, immune, endocrine and metabolic routes. This narrative review synthesizes recent preclinical, mechanistic and early clinical observations. Experimental studies show that selected strains can modulate cytokine signalling, influence stress‐responsive systems such as the hypothalamic–pituitary–adrenal axis, and support synaptic plasticity via factors such as brain‐derived neurotrophic factor. A limited number of human trials using well‐characterized Lactobacillus and Bifidobacterium strains have reported improvements in affective and stress‐related outcomes, but these effects are generally small to moderate, more apparent in adjunctive than stand‐alone use, and dependent on strain, dose, population and intervention length (typically 4–12 weeks). Evidence on neurodevelopmental conditions (e.g., autism spectrum disorder, attention‐deficit/hyperactivity disorder) remains preliminary, based on small and heterogeneous samples. Across studies, key constraints include methodological heterogeneity, incomplete strain‐level reporting, and gaps in mechanistic resolution that make it difficult to link microbial shifts to psychiatric benefit. Emerging microbiome‐ and metabolomics‐informed approaches may help identify likely responders and improve translational precision, but they are not yet ready for routine clinical application. Overall, psychobiotics should currently be viewed as a promising adjunct within integrative mental health care, warranting larger, standardized trials with clearly defined strains, doses and mechanistic endpoints.
- 26 February 2026
- Published by Elsevier in Behavioural Brain Research
- Vol. 505, 116138
Modulating glymphatic clearance in Alzheimer’s disease: Molecular mechanisms, imaging biomarkers, and emerging interventions
- 26 February 2026
- Published by Elsevier in Behavioural Brain Research
- Vol. 505, 116138
Modulating glymphatic clearance in Alzheimer’s disease: Molecular mechanisms, imaging biomarkers, and emerging interventions
- Open Access
- 6 January 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (4) , 1733-1745
Immunomodulatory effects of cathelicidin in the gut–brain axis: A novel link between mucosal immunity and neuroinflammation
Cathelicidins are evolutionarily conserved host defence peptides known for their dual antimicrobial and immunomodulatory functions. Among them, LL‐37 in humans and CRAMP in rodents have emerged as crucial regulators of both mucosal immunity and CNS inflammation. This review explores the emerging evidence that positions cathelicidins as key modulators of the gut–brain axis, a bidirectional communication network increasingly implicated in neuroinflammatory and neurodegenerative disorders. Drawing on a diverse body of animal and human research, we examine the multifaceted roles of cathelicidin in maintaining intestinal barrier integrity, shaping microbiota composition and regulating innate immune signalling. Particular attention is paid to how gut‐derived metabolites, such as short‐chain fatty acids and vitamin D, influence cathelicidin expression, with downstream consequences for both gastrointestinal and neural health. In the CNS, cathelicidin exhibits context‐dependent effects, acting as a neuroprotective modulator when derived from neurons, but exacerbating glial‐mediated inflammation when sourced from peripheral immune cells. This functional dichotomy underscores the importance of cellular origin, concentration and microenvironmental cues. Furthermore, we delineate how cathelicidin facilitates crosstalk between peripheral and central compartments, serving as both a local effector and a systemic messenger. Collectively, these insights support a reconceptualization of cathelicidin not merely as a passive antimicrobial peptide, but as an active molecular bridge between mucosal immunity and neuroinflammation, with promising implications for diagnostics and therapeutics targeting dysfunction of the gut–brain axis.
- 6 January 2026
- Published by Wiley in Experimental Physiology
- Vol. 111 (4) , 1733-1745
Open AccessImmunomodulatory effects of cathelicidin in the gut–brain axis: A novel link between mucosal immunity and neuroinflammation
Cathelicidins are evolutionarily conserved host defence peptides known for their dual antimicrobial and immunomodulatory functions. Among them, LL‐37 in humans and CRAMP in rodents have emerged as crucial regulators of both mucosal immunity and CNS inflammation. This review explores the emerging evidence that positions cathelicidins as key modulators of the gut–brain axis, a bidirectional communication network increasingly implicated in neuroinflammatory and neurodegenerative disorders. Drawing on a diverse body of animal and human research, we examine the multifaceted roles of cathelicidin in maintaining intestinal barrier integrity, shaping microbiota composition and regulating innate immune signalling. Particular attention is paid to how gut‐derived metabolites, such as short‐chain fatty acids and vitamin D, influence cathelicidin expression, with downstream consequences for both gastrointestinal and neural health. In the CNS, cathelicidin exhibits context‐dependent effects, acting as a neuroprotective modulator when derived from neurons, but exacerbating glial‐mediated inflammation when sourced from peripheral immune cells. This functional dichotomy underscores the importance of cellular origin, concentration and microenvironmental cues. Furthermore, we delineate how cathelicidin facilitates crosstalk between peripheral and central compartments, serving as both a local effector and a systemic messenger. Collectively, these insights support a reconceptualization of cathelicidin not merely as a passive antimicrobial peptide, but as an active molecular bridge between mucosal immunity and neuroinflammation, with promising implications for diagnostics and therapeutics targeting dysfunction of the gut–brain axis.